Expansion of PathFlow® COVID-19 lateral flow test portfolio

Paris, France and Camberley, UK – 29 June 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is to launch two PathFlow® COVID-19 antigen lateral flow tests (LFTs) to strengthen the Company’s COVID-19 portfolio and to pursue significant new market opportunities, especially in point-of-care (POC) settings. The Company will initially target private market opportunities for these LFTs via its existing distribution network.

http://novacyt.com/wp-content/uploads/2021/06/Novacyt-Expansion-of-PathFlow®-COVID-19-final.pdf